<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341377</url>
  </required_header>
  <id_info>
    <org_study_id>SCCHEC-02-2017-042</org_study_id>
    <nct_id>NCT03341377</nct_id>
  </id_info>
  <brief_title>Perioperative Symptom Study of Lung Cancer (CN-PRO-Lung 1)</brief_title>
  <official_title>An Observational Study for Establishing the Patient-reported Outcome-based Perioperative Symptom Management Cohort in Patients With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaojun Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zigong First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangyou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Seventh People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dazhu County People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Cancer Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose a multicenter prospective observational cohort study to develop and&#xD;
      validate essential technical parameters for establishing the patient-reported outcome-based&#xD;
      perioperative symptom management cohort in patients with lung cancer. With at least 300&#xD;
      patients with initial diagnosis of lung cancer and scheduled for surgery, this study will&#xD;
      administer symptom assessments (MDASI-LC) and quality of life assessments (SIQOL) before&#xD;
      surgery (typically within 3 days before surgery), daily after surgery (in hospital ≤ 14&#xD;
      days), and weekly after discharge, up to 4 weeks (±3 days) or the start day of postoperative&#xD;
      oncologic treatment. In the upgraded research protocol, symptom and quality of life&#xD;
      assessments (every 3 month for 1 year, every 6 month for 2-3 year, every 12 month for 4-5&#xD;
      year), as well as the follow-up of clinical outcomes will continue until 5 years after&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative symptom burden (severity, freqency and impact on daily functioning) measured by MDASI-LC</measure>
    <time_frame>less than 6 weeks</time_frame>
    <description>We will use MD Anderson Symptom Inventory lung cancer module (MDASI-LC) to longitudinally assess the perioperative symptom burden for lung cancer patients. The symptom burden will be profiled as symptom severity, frequency of moderate to severe symptom and its interference with daily functioning.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">512</enrollment>
  <condition>Patient-reported Outcomes</condition>
  <arm_group>
    <arm_group_label>Lung cancer surgical patients</arm_group_label>
    <description>Patient-reported symptom assessments in patients undergoing lung cancer surgery.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Lung cancer patients planning to undergo surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be pathologically or clinically diagnosed as primary lung cancer before surgery;&#xD;
&#xD;
          2. Plan to undergo a surgical procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Aged younger than 18;&#xD;
&#xD;
          2. Diagnosis of cognitive impairment or unable to understand the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan Cancer Hospital and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital and Research Institute</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chengdu Seventh People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chengdu Third People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dazhu County People's Hospital</name>
      <address>
        <city>Dazhou</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangyou People's Hospital</name>
      <address>
        <city>Jiangyou</city>
        <state>Sichuan</state>
        <zip>621700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zigong First People's Hospital</name>
      <address>
        <city>Zigong</city>
        <state>Sichuan</state>
        <zip>643000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>October 25, 2020</last_update_submitted>
  <last_update_submitted_qc>October 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Xiaojun Yang</investigator_full_name>
    <investigator_title>Clinical Professor and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>utility parameter</keyword>
  <keyword>patient-reported outcome</keyword>
  <keyword>perioperative symptom management</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

